Asia Book of Records Honors Cipla (Emerging Markets&Europe business unit) for Record-Breaking Doctor engagement on COPD Awareness Initiative
Cipla's (EMEU BU)'Take Charge – I Pledge'campaign engaged 4,350 doctors across six countries, setting a new benchmark in raising COPD awareness.
MUMBAI, India,Jan. 29, 2025/PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as"Cipla"today announced that itsEmerging Markets& Europe Business Unit (EMEU BU)has achieved a new milestone by being recognized in the Asia Book of Records. During COPD Awareness Month, Cipla successfully engaged 4,350 doctors fromNepal,Myanmar,Sri Lanka,Malaysia,Oman, and the UAEin a pledge campaign to raise awareness about Chronic Obstructive Pulmonary Disease (COPD). The initiative, titled'Take Charge – I Pledge,'aimed to foster meaningful dialogue between healthcare professionals, patients, and caregivers, reinforcing Cipla's commitment to respiratory disease awareness.
This achievement has been recognised by the Asia Book of Records for engaging the largest number of doctors in a COPD awareness campaign during COPD Awareness Month.
Commenting on this recognition,Swapn Malpani, CEO – Cipla EMEUsaid,"COPD is recognized as a progressive lung condition and ranks as the fourth leading cause of death worldwide. In 2021, it accounted for about 3.5 million deaths, which is roughly 5% of all deaths globally. By encouraging doctors to participate in the'Take Charge – I Pledge'campaign, our aim was to highlight the significance of timely diagnosis and effective management in enhancing long-term health outcomes. The campaign aimed to strengthen the doctor-patient relationship by promoting open dialogue, which can result in better understanding and improved care for those living with COPD."
About Cipla
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets ofIndia,South Africa,North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rdlargest in pharma inIndia(IQVIA MAT Dec'24), Largest in the pharma prescription market inSouth Africa(IQVIA MAT Nov'24), and 4thlargest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Nov'24). For more, please visitwww.cipla.com, or click onTwitter, Facebook, LinkedIn.
Media Contact:
Investor Relations
E-mail:Investor.Relations@cipla.com
View original content:SOURCE Cipla
허블 정보
Copyright © 2017 Huvle All Rights Reserved
admin@huvle.com